Discover
ZNTL
Zentalis Pharmaceuticals, Inc.
3.11
2 x 3.53
2 x 6.28
bid
ask
+
0.03
0.97%
2 @ 04:00 PM
3.24 +0.13 (4.18%)
| Ytd | 130.37% | |
| 1y | 108.72% |
2.99
day range
3.18
1.21
52 week range
6.95
| Open | 3.07 | Prev Close | 3.08 | Low | 2.99 | High | 3.18 | Mkt Cap | 294.43M |
| Vol | 1.26M | Avg Vol | 1.23M | EPS | -1.96 | P/E | N/A | Forward P/E | -0.89 |
| Beta | 1.74 | Short Ratio | 3.17 | Inst. Own | 98.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 4.15 | 200-d Avg | 3.35 | 1yr Est | 9.50 |
| Income Statement | |||
| Operating Expenses | 44.39M | ||
| Research and Development Expense | 35.16M | ||
| Selling, General and Administrative Expense | 9.23M | ||
| Operating Income | -44.39M | ||
| Income Tax Expense | 138.00K | ||
| Net Income | -42.29M | ||
| Net Income Common Stock | -42.29M | ||
| Net Income Common Stock (USD) | -42.29M | ||
| Consolidated Income | -42.29M | ||
| Earnings per Basic Share | -0.59 | ||
| Earnings per Basic Share (USD) | -0.59 | ||
| Earnings per Diluted Share | -0.59 | ||
| Earning Before Interest & Taxes (EBIT) | -42.15M | ||
| Earning Before Interest & Taxes (USD) | -42.15M | ||
| Weighted Average Shares | 71.33M | ||
| Weighted Average Shares Diluted | 71.33M | ||
| Balance Sheet | |||
| Cash and Equivalents | 27.41M | ||
| Cash and Equivalents (USD) | 27.41M | ||
| Investments | 149.82M | ||
| Investments Current | 149.82M | ||
| Current Assets | 181.28M | ||
| Property, Plant & Equipment Net | 27.30M | ||
| Total Assets | 215.33M | ||
| Total Debt | 33.56M | ||
| Current Liabilities | 37.63M | ||
| Debt Non-Current | 33.56M | ||
| Total Liabilities | 71.68M | ||
| Accumulated Retained Earnings (Deficit) | -1.27B | ||
| Accumulated Other Comprehensive Income | -78.00K | ||
| Shareholders Equity | 143.65M | ||
| Shareholders Equity (USD) | 143.65M | ||
| Assets Non-Current | 34.05M | ||
| Total Debt (USD) | 33.56M | ||
| Liabilities Non-Current | 34.06M | ||
| Trade and Non-Trade Payables | 8.14M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 153.00K | ||
| Net Cash Flow from Financing | 65.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -7.15M | ||
| Issuance (Purchase) of Equity Shares | 65.00K | ||
| Net Cash Flow from Investing | 30.02M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 30.02M | ||
| Net Cash Flow from Operations | -37.24M | ||
| Share Based Compensation | 3.22M | ||